Search research articles
Contact Us
Filters
Showing results (91-100 of 148) with videos related to
Page
of 15
Sort By:
The Journal of Infectious Diseases
|
February 3, 2005
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
Peter B Gilbert, Michael L Peterson, Dean Follmann, et al.
BMJ Open
|
March 3, 2025
Demographics, epidemiology, mortality and difficult-to-treat resistance patterns of bacterial bloodstream infections in the global US Military Health System from 2010 to 2019: a retrospective cohort study
Alexander C Vostal, Melissa Grance, John H Powers, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
October 11, 2023
Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial
Nima S Hejazi, Xiaoying Shen, Lindsay N Carpp, et al.
Plos Pathogens
|
February 28, 2009
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man
Jean K Lim, Andrea Lisco, David H McDermott, et al.
The Journal of Infectious Diseases
|
December 4, 2012
Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1
Amanda Hurley, Mindy Smith, Tatiana Karpova, et al.
American Journal of Epidemiology
|
August 21, 2025
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up
Ethan Ashby, Holly Janes, Dean Follmann, et al.
Open Forum Infectious Diseases
|
December 16, 2024
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial
Dean Follmann, Xiaowei Wang, Lindsey R Baden, et al.
The Journal of Infectious Diseases
|
November 25, 2025
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood Samples
Dean Follmann, Lauren Dang, Eric Chu, et al.
Nature Communications
|
October 14, 2025
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19
Rhiannon Edge, Sam Matthews, Bahar Ahani, et al.
American Journal of Infection Control
|
March 3, 2019
Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms
Sameer S Kadri, Jeffrey R Strich, Bruce J Swihart, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 148) with videos related to
Sort By:
Page
of 15
The Journal of Infectious Diseases
|
February 3, 2005
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
Peter B Gilbert, Michael L Peterson, Dean Follmann, et al.
BMJ Open
|
March 3, 2025
Demographics, epidemiology, mortality and difficult-to-treat resistance patterns of bacterial bloodstream infections in the global US Military Health System from 2010 to 2019: a retrospective cohort study
Alexander C Vostal, Melissa Grance, John H Powers, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
October 11, 2023
Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial
Nima S Hejazi, Xiaoying Shen, Lindsay N Carpp, et al.
Plos Pathogens
|
February 28, 2009
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man
Jean K Lim, Andrea Lisco, David H McDermott, et al.
The Journal of Infectious Diseases
|
December 4, 2012
Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1
Amanda Hurley, Mindy Smith, Tatiana Karpova, et al.
American Journal of Epidemiology
|
August 21, 2025
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up
Ethan Ashby, Holly Janes, Dean Follmann, et al.
Open Forum Infectious Diseases
|
December 16, 2024
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial
Dean Follmann, Xiaowei Wang, Lindsey R Baden, et al.
The Journal of Infectious Diseases
|
November 25, 2025
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood Samples
Dean Follmann, Lauren Dang, Eric Chu, et al.
Nature Communications
|
October 14, 2025
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19
Rhiannon Edge, Sam Matthews, Bahar Ahani, et al.
American Journal of Infection Control
|
March 3, 2019
Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms
Sameer S Kadri, Jeffrey R Strich, Bruce J Swihart, et al.
Page
of 15